Great brainstorming session today at #EMUC25 focused on advancing the most current insights in urothelial carcinoma research 🚀

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

🚨Online now: TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in muscle-invasive #bladdercancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a phase 2 trial https://t.co/MOH1m04kge

Our SEER-based study shows that pts with cN+ M0 bladder cancer who received chemotherapy + radical cystectomy had better CSS and OS compared to those who had chemoradiation. The 5-yr OS was only 25%. https://t.co/sjsZOlStnf @Pietro9609 @UroMoschini @BenjaminPradere @SBoorjian

Thank you for the opportunity to speak at UROonco25 during the Best of Onco-Urology Journals session! @EAU_Uroonco @foxal72 @MRoupret @EAU_YAUrotheli

Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment @Uroweb @EAU_Uroonco @EAUYAUrology

Dziękuję @FNP_org_pl za przyznanie stypendium START! To dla mnie ogromne wyróżnienie i motywacja do dalszej pracy badawczej! #JestemStartowcem #MłodaPolskaNauka #FNP

Simple pre-op factors can reliably predict kidney function 1 year after partial nephrectomy for RCC. 🔍 Linear regression performed as well as advanced machine-learning models. 📊 Predictors: baseline GFR, tumor size, comorbidities. https://t.co/Li4cKzl1sV @Cancers_MDPI

Adequate vs inadequate BCG: 5-yr HG-RFS 83% vs 68% 5-yr PFS 92% vs 85% in the IPTW-adjusted Kaplan-Meier analyses

Our multicenter study including 1558 NMIBC pts validates the IBCG definition of adequate BCG, and demonstrates that adequate BCG is associated with superior long-term HG RFS and PFS compared to inadequate BCG @european_focus @EAU_YAUrotheli @UroMoschini https://t.co/V5YLuql4lB

📣 Very High-risk NMIBC: real-world data challenge guidelines on upfront radical cystectomy. Happy to share our @EUplatinum editorial Thanks @UroDocAsh, @RobertoContieri , @Renate_Pichler , #PietroScilipoti, @niyatilobo for your support 🙏 #BladderCancer #Urology #Oncology

Review – Bladder Cancer: The Financial Burden of Localized and Metastatic Bladder Cancer by Pietro Scilipoti, @UroMoschini et al Read the full article here: https://t.co/HQjcHFQtXj #UroSoMe #MedTwitter #EurUrol #BladderCancer

Radical cystectomy vs bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the comparison of intravesical therapy and surgery as treatment. The #CISTO study. Presented by John Gore, MD, MS, FACS @UW. #AUA25 written coverage by

Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized The latest @IBCG_BladderCA consensus in @EUplatinum offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate

Our meta-analysis of 50 prospective studies demonstrates promising short-term oncological outcomes of focal therapy in clinically localized PCa and a favorable safety profile. @EurUrolOncol

Our new SR and MA published in @EurUrolOncol evaluates focal therapy for localized PCa using prospective data only. Important for patient counselling. 📊 50 studies, 4,615 patients 📊 12-mo csPCa RFS in intermediate-risk: 79% (95% CI 74–83%) 🔗 https://t.co/jkiz7WlcRY

Real-world data on nadofarogene firadenovec for BCG-unresponsive #BladderCancer. @MarkTysonMD @MayoClinic & Jacob Moyer join @UroDocAsh @MDAndersonNews to share real-world data on nadofarogene firadenovec in BCG-unresponsive #NMIBC, showing 79% CR in CIS & 68% in papillary-only

Our meta-analysis of two RCTs shows that extended LND does not improve RFS or OS compared to standard LND but leads to higher morbidity in bladder cancer patients undergoing RC @UroMoschini @BenjaminPradere @wjurol

Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response on long-term outcomes from #NIAGARA. Perioperative durvalumab + chemo in #MIBC shows: ✅ 33% ↓ risk of metastasis/death (HR 0.67) ✅ 31% ↓ risk of bladder

Our editorial on the #BladderPath study: Could MRI-first staging streamline MIBC treatment? Skipping TURBT may reduce delays—especially for those needing palliative care or radiotherapy. @JCO_ASCO @AndreaNecchi @JimCatto @Prof_Nick_James #OncSurgery #BladderCancer